What Happened
The FDA has refreshed its public guidance on unapproved and compounded GLP-1 drugs, and the new material is unusually operational. Patients are now told to discard multi-dose vials within 28 days of first use — even if medication remains, and even if the compounder's instructions say otherwise — and to use a new sterile needle and syringe for every dose. The agency frames this as a contamination threshold, not a potency claim.
Two additions matter more for the supply side. The FDA says it has received complaints that compounded GLP-1 injectables arrived warm or with inadequate ice packs, and advises against using any injectable GLP-1 that arrives warm because quality may be affected. The agency also confirmed a green list import alert (66-80) meant to stop GLP-1 active pharmaceutical ingredients with potential quality concerns at the border, with API from manufacturers FDA has evaluated as compliant carved out.
The guidance restates a hard legal line: retatrutide and cagrilintide cannot be used in compounding under federal law. Neither is a component of an FDA-approved drug, the agency writes, and neither "has been found safe and effective for any condition."
Who Is Affected
- Patients on compounded semaglutide or tirzepatide in multi-dose vials, where a 28-day discard rule can waste paid-for medication.
- Compounding pharmacies and outsourcing facilities — vial dating, cold-chain documentation and API sourcing are now on the checklist.
- Telehealth platforms shipping injectables without validated cold chain, or describing a compounded product as equivalent to an approved one.
- Research-peptide buyers, who meet the same compounds sold as "for research purposes only" — a label the agency treats as a dodge when the product ships with dosing instructions.
Timeline
- May 31, 2026 — FDA's tally: 990 adverse event reports tied to compounded semaglutide, more than 730 to compounded tirzepatide. State-licensed pharmacies outside the outsourcing system need not report, so the real figure is higher.
- September–October 2026 — Warning letters to telehealth firms, API distributors and outsourcing facilities over retatrutide.
- November 6, 2026 — Refreshed guidance draws national attention; the 28-day vial limit, warm-shipment advisory and import alert become the operative checklist.
- Ongoing — Border screening of GLP-1 API, with compliant manufacturers carved out.
What This Means for Researchers
Read the guidance as a chain-of-custody document. Three of its four new items concern what happens after the vial leaves the pharmacy: how long an opened multi-dose vial is usable, whether it stayed cold in transit, and whether raw material cleared a border screen.
The cold-chain language cuts differently for freeze-dried material than for ready-to-use liquid. A lyophilized vial is expected to ship at ambient temperature; a pre-mixed liquid arriving warm is the failure mode described. The import alert has the longest tail — grey-market API flows toward the cheapest documentation, and a green list narrows the field. Treat an unnamed API source as an open question, not a neutral one.
How to Verify Your Peptides
Independent testing is the only substitute for the documentation a regulated chain would provide. Start with how peptide testing works, then what a certificate of analysis should contain on identity, purity and fill weight. If a vendor publishes only a purity number with no method, HPLC versus LC-MS explains what it can and cannot tell you.
Safe Alternatives
- Retatrutide — the compound the FDA says cannot be legally compounded, and the one drawing the most counterfeit supply.
- Semaglutide and tirzepatide — the approved backbones behind most compounded copies.
- Cagrilintide guide — the second compound named in the uncompoundable ruling.
- Vendor directory — documentation and testing signals side by side.
Sources
Regulatory announcements and industry reports. Figures reflect agency tallies as published, with the agency's own caveat that reporting is incomplete.